We are live on ! Find out more
RGLS

Regulus Therapeutics
RGLS

Delisted

RGLS was delisted on the 24th of June, 2025.

Back to rankings

46 hedge funds and large institutions have $34.2M invested in Regulus Therapeutics in 2018 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 6 increasing their positions, 11 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.01% less ownership

Funds ownership: 0.43% → 0.41% (-0.01%)

8% less funds holding

Funds holding: 50 → 46 (-4)

10% less capital invested

Capital invested by funds: $38.1M → $34.2M (-$3.9M)

40% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 10

45% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 11

Holders
46
Holders Change
-4
Holders Change %
-8%
% of All Funds
1.05%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
6
Reduced
11
Closed
10
Calls
$8K
Puts
–
Net Calls
+$8K
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
AC
Ascend Capital
California
+$46K
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$37.2K
3
Invesco
Invesco
Georgia
+$14K
4
Goldman Sachs
Goldman Sachs
New York
+$11.5K
5
BAS
Brown Advisory Securities
Maryland
+$10.3K

Top Sellers

Rank Fund Capital Flow
1
BI
BVF Inc
California
-$199K
2
DZ Bank
DZ Bank
Germany
-$147K
3
BlackRock
BlackRock
New York
-$135K
4
ARTA
A.R.T. Advisors
New York
-$91.7K
5
Vanguard Group
Vanguard Group
Pennsylvania
-$89.1K
Name Holding Trade Value Shares
Change 		Change in
Stake
HighTower Advisors
26
HighTower Advisors
Illinois
$14K – – –
Macquarie Group
27
Macquarie Group
Australia
$13K – – –
TRCT
28
Tower Research Capital (TRC)
New York
$13K +$8.36K +101 +166%
Invesco
29
Invesco
Georgia
$13K +$14K +169 New
Goldman Sachs
30
Goldman Sachs
New York
$11K +$11.5K +139 New
IA
31
IFP Advisors
Florida
$10K – – –
Mariner
32
Mariner
Kansas
$10K – – –
BAS
33
Brown Advisory Securities
Maryland
$10K +$10.3K +125 New
UBS Group
34
UBS Group
Switzerland
$10K +$10.3K +125 New
BCM
35
Bourgeon Capital Management
Connecticut
$9K – – –
BCM
36
Brookstone Capital Management
Illinois
$9K – – –
DY
37
Dowling & Yahnke
California
$8K – – –
LTFS
38
Ladenburg Thalmann Financial Services
Florida
$6K – – –
MAM
39
Meeder Asset Management
Ohio
$4.9K +$1.16K +14 +29%
Manulife (Manufacturers Life Insurance)
40
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$4K – – –
FDCDDQ
41
Federation des caisses Desjardins du Quebec
Quebec, Canada
$1.32K – – –
Morgan Stanley
42
Morgan Stanley
New York
$1K – – –
JP Morgan Chase
43
JP Morgan Chase
New York
$1K +$579 +7 New
SPIA
44
Steward Partners Investment Advisory
New York
$1K +$662 +8 New
BNP Paribas Financial Markets
45
BNP Paribas Financial Markets
France
$3 – – –
DZ Bank
46
DZ Bank
Germany
– -$147K -1,706 Closed
VF
47
Virtu Financial
New York
– -$56K -655 Closed
GC
48
Guggenheim Capital
Illinois
– -$19K -217 Closed
TSS
49
Two Sigma Securities
New York
– -$14K -158 Closed
AGM
50
Alpine Global Management
New York
– -$7K -85 Closed
1
2
3

RGLS Hedge Fund Activity: Q2 2018 in Review

46 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Regulus Therapeutics (RGLS) for Q2 2018, worth a combined $34.2M — down 10% from $38.1M a quarter earlier.

Sellers outnumbered buyers: 10 funds closed out of RGLS and 6 opened new positions — a net loss of 4 holders — while 11 trimmed existing stakes and 6 added.

The largest buyer was Ascend Capital, adding an estimated $46K. The largest seller was BVF Inc, cutting an estimated $199K.

  • 46 institutional investors held Regulus Therapeutics (RGLS) as of Q2 2018, down from 50 in Q1 2018.
  • Funds reported $34.2M of Regulus Therapeutics stock for Q2 2018, down 10% quarter-over-quarter.
  • 6 funds opened new Regulus Therapeutics positions in Q2 2018 and 10 closed out, a net change of -4 holders.
  • The largest Regulus Therapeutics buyer in Q2 2018 was Ascend Capital, an estimated $46K added.
  • The largest Regulus Therapeutics seller in Q2 2018 was BVF Inc, an estimated $199K sold.

Based on aggregated 13F filings for Q2 2018.